Musculoskeletal disorders and coronary artery disease —promising molecular markers: literature review
- 作者: Karetnikova V.1,2, Neeshpapa A.1, Carpova E.1, Barbarash O.1,2
-
隶属关系:
- Research Institute for Complex Issues of Cardiovascular Diseases
- Kemerovo State Medical University
- 期: 卷 15, 编号 1 (2024)
- 页面: 55-70
- 栏目: Reviews
- URL: https://journals.rcsi.science/2221-7185/article/view/256937
- DOI: https://doi.org/10.17816/CS624809
- ID: 256937
如何引用文章
全文:
详细
Currently, increasing evidence shows that people with cardiovascular diseases, including coronary heart disease, have a higher risk of developing pathologies such as sarcopenia, osteopenia, osteosarcopenia, sarcopenic, and osteosarcopenic obesity, which is associated with increased mortality risk. Musculoskeletal and adipose tissue changes have significantly affected the quality of life of patients and are important clinical problems. It is assumed that between the aforementioned disorders and coronary heart disease, a pathogenetic connection with the possibility of mutual aggravation exists. Accordingly, the search for relevant and accurate markers that reflect the severity and characterize the prognosis of a complex of pathological conditions is necessary given the increased proportion of patients in the general population with comorbidities. The article reviews the basic concepts of age-related disorders of body composition and molecular markers and emphasizes on new and potentially promising ones. The results can help in identifying and assessing the severity and prognosis of atherosclerosis, including coronary heart disease, and various disorders of musculoskeletal homeostasis, which reflects the commonality of their pathogenesis.
作者简介
Viktoria Karetnikova
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Email: tori1071@mail.ru
ORCID iD: 0000-0002-9801-9839
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Kemerovo; KemerovoAnastasiya Neeshpapa
Research Institute for Complex Issues of Cardiovascular Diseases
编辑信件的主要联系方式.
Email: anastasiyaneeshpapa@mail.ru
ORCID iD: 0000-0002-6808-9959
MD, Cand. Sci. (Med.)
俄罗斯联邦, KemerovoEvgenia Carpova
Research Institute for Complex Issues of Cardiovascular Diseases
Email: iameviss1@yandex.ru
ORCID iD: 0009-0005-9057-3535
俄罗斯联邦, Kemerovo
Olga Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Email: karevn@kemcardio.ru
ORCID iD: 0000-0002-4642-3610
MD, Dr. Sci. (Med.), Professor, Academician of RAS
俄罗斯联邦, Kemerovo; Kemerovo参考
- Casati M, Costa AS, Capitanio D, et al. The Biological Foundations of Sarcopenia: Established and Promising Markers. Front Med (Lausanne). 2019;(6):184. doi: 10.3389/fmed.2019.00184
- Lee K. Association of osteosarcopenic obesity and its components: osteoporosis, sarcopenia and obesity with insulin resistance. J Bone Miner Metab. 2020;38(5):695–701. doi: 10.1007/s00774-020-01104-2
- Keramidaki K, Tsagari A, Hiona M, Risvas G. Osteosarcopenic obesity, the coexistence of osteoporosis, sarcopenia and obesity and consequences in the quality of life in older adults ≥65 years-old in Greece. J Frailty Sarcopenia Falls. 2019;4(4):91–101. doi: 10.22540/JFSF-04-091
- Zhang N, Zhu WL, Liu XH, et al. Prevalence and prognostic implications of sarcopenia in older patients with coronary heart disease. J Geriatr Cardiol. 2019;16(10):756–763. doi: 10.11909/j.issn.1671-5411.2019.10.002
- Hong SH, Choi KM. Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. Int J Mol Sci. 2020;21(2):494. doi: 10.3390/ijms21020494
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019;48(4):601.
- Uchida S, Kamiya K, Hamazaki N, et al. Association between sarcopenia and atherosclerosis in elderly patients with ischemic heart disease. Heart Vessels. 2020;35(6):769–775. doi: 10.1007/s00380-020-01554-8
- He N, Zhang Y, Zhang L, et al. Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview. Front Cardiovasc Med. 2021;(8):743710. doi: 10.3389/fcvm.2021.743710
- Xia N, Cai Y, Wang W, et al. Association of bone-related biomarkers with femoral neck bone strength. BMC Musculoskelet Disord. 2022;23(1):482. doi: 10.1186/s12891-022-05427-1
- Khandkar C, Vaidya K, Karimi Galougahi K, Patel S. Low bone mineral density and coronary artery disease: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021;(37):100891. doi: 10.1016/j.ijcha.2021.100891
- den Uyl D, Nurmohamed MT, van Tuyl LH, et al. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011;13(1):R5. doi: 10.1186/ar3224
- Grebennikova TA, Tsoriev TT, Vorobeva JR, Belaya ZE. Osteosarcopenia: pathogenesis, diagnosis and therapeutic approaches. Annals of the Russian academy of medical sciences. 2020;75(3):240–249. doi: 10.15690/vramn1243
- Fahimfar N, Parsaiyan H, Khalagi K, et al. The Association of Cardiovascular Diseases Risk Scores and Osteosarcopenia Among Older Adult Populations: The Results of Bushehr Elderly Health (BEH) Program. Calcif Tissue Int. 2023;112(4):422–429. doi: 10.1007/s00223-022-01059-8
- Caffarelli C, Al Refaie A, Baldassini L, et al. Bone fragility, sarcopenia and cardiac calcifications in an elderly population: a preliminary study. Aging Clin Exp Res. 2023;35(5):1097–1105. doi: 10.1007/s40520-023-02393-z
- Park CH, Lee YT, Yoon KJ. Association between osteosarcopenia and coronary artery calcification in asymptomatic individuals. Sci Rep. 2022;12(1):2231. doi: 10.1038/s41598-021-02640-1
- Berns SA, Sheptulina AF, Mamutova EM, et al. Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria. Cardiovascular Therapy and Prevention. 2023;22(6):78–85. doi: 10.15829/1728-8800-2023-3576
- Santana NM, Mendes RML, Silva NFD, Pinho CPS. Sarcopenia and sarcopenic obesity as prognostic predictors in hospitalized elderly patients with acute myocardial infarction. Einstein (Sao Paulo). 2019;17(4):eAO4632. doi: 10.31744/einstein_journal/2019AO4632
- Sato R, Okada K, Akiyama E, et al. Impact of sarcopenic obesity on long-term clinical outcomes after ST-segment elevation myocardial infarction. Atherosclerosis. 2021;(335):135–141. doi: 10.1016/j.atherosclerosis.2021.08.038
- Silveira EA, da Silva Filho RR, Spexoto MCB, et al. The Role of Sarcopenic Obesity in Cancer and Cardiovascular Disease: A Synthesis of the Evidence on Pathophysiological Aspects and Clinical Implications. Int J Mol Sci. 2021;22(9):4339. doi: 10.3390/ijms22094339
- Li F, Bai T, Ren Y, et al. A systematic review and meta-analysis of the association between sarcopenia and myocardial infarction. BMC Geriatr. 2023;23(1):11. doi: 10.1186/s12877-022-03712-1
- Hu K, Deya Edelen E, Zhuo W, et al. Understanding the Consequences of Fatty Bone and Fatty Muscle: How the Osteosarcopenic Adiposity Phenotype Uncovers the Deterioration of Body Composition. Metabolites. 2023;13(10):1056. doi: 10.3390/metabo13101056
- Cardoso AL, Fernandes A, Aguilar-Pimentel JA, et al. Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases. Ageing Res Rev. 2018;(47):214–277. doi: 10.1016/j.arr.2018.07.004
- Sato R, Vatic M, da Fonseca GWP, von Haehling S. Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature? Curr Heart Fail Rep. 2022;19(6):400–411. doi: 10.1007/s11897-022-00575-w
- Macari S, Madeira MFM, Lima ILA, et al. ST2 regulates bone loss in a site-dependent and estrogen-dependent manner. J Cell Biochem. 2018;119(10):8511–8521. doi: 10.1002/jcb.27080
- Hughes MF, Appelbaum S, Havulinna AS, et al. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart. 2014;100(21):1715–1721. doi: 10.1136/heartjnl-2014-305968
- Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014;9(4):e95055. doi: 10.1371/journal.pone.0095055
- Zhang J, Chen Z, Ma M, He Y. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Front Cardiovasc Med. 2022;(9):924461. doi: 10.3389/fcvm.2022.924461
- Alcalde-Estévez E, Asenjo-Bueno A, Sosa P, et al. Endothelin-1 induces cellular senescence and fibrosis in cultured myoblasts. A potential mechanism of aging-related sarcopenia. Aging (Albany NY). 2020;12(12):11200–11223. doi: 10.18632/aging.103450
- Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16(8):491–502. doi: 10.1038/s41569-019-0176-3
- Goudhaman L, Raja Jagadeesan A, Sundaramoorthi S, et al. Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: A Pilot Study. Rep Biochem Mol Biol. 2021;10(2):302–306. doi: 10.52547/rbmb.10.2.302
- Xie Z, Hou L, Shen S, et al. Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation. Nat Commun. 2022;13(1):50. doi: 10.1038/s41467-021-27629-2
- Yokoro M, Otaki N, Yano M, et al. Association between asymmetric dimethylarginine and sarcopenia in community-dwelling older women. Sci Rep. 2023;13(1):5510. doi: 10.1038/s41598-023-32046-0
- Petermann-Rocha F, Gray SR, Pell JP, et al. Biomarkers Profile of People With Sarcopenia: A Cross-sectional Analysis From UK Biobank. J Am Med Dir Assoc. 2020;21(12):2017.e1–2017.e9. doi: 10.1016/j.jamda.2020.05.005
- Shin HE, Walston JD, Kim M, Won CW. Sex-Specific Differences in the Effect of Free Testosterone on Sarcopenia Components in Older Adults. Front Endocrinol (Lausanne). 2021;(12):695614. doi: 10.3389/fendo.2021.695614. Erratum in: Front Endocrinol (Lausanne). 2022;(13):876640.
- Kirby M, Hackett G, Ramachandran S. Testosterone and the Heart. Eur Cardiol. 2019;14(2):103–110. doi: 10.15420/ecr.2019.13.1
- Elagizi A, Köhler TS, Lavie CJ. Testosterone and Cardiovascular Health. Mayo Clin Proc. 2018;93(1):83–100. doi: 10.1016/j.mayocp.2017.11.006
- Islam RM, Bell RJ, Handelsman DJ, et al. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev. 2022;3(2):e109–e118. doi: 10.1016/S2666-7568(22)00001-0. Erratum in: Lancet Healthy Longev. 2023;4(8):e373.
- Heinze-Milne S, Banga S, Howlett SE. Low testosterone concentrations and risk of ischaemic cardiovascular disease in ageing: not just a problem for older men. Lancet Healthy Longev. 2022;3(2):e83–e84. doi: 10.1016/S2666-7568(22)00008-3
- Shigehara K, Izumi K, Kadono Y, Mizokami A. Testosterone and Bone Health in Men: A Narrative Review. J Clin Med. 2021;10(3):530. doi: 10.3390/jcm10030530
- Alalwan TA. Phenotypes of Sarcopenic Obesity: Exploring the Effects on Peri-Muscular Fat, the Obesity Paradox, Hormone-Related Responses and the Clinical Implications. Geriatrics (Basel). 2020;5(1):8. doi: 10.3390/geriatrics5010008
- Sergeeva NS, Karmakova TA, Alentov II, et al. Clinical significanse of prostate-specific antigen in breast cancer patients. Siberian journal of oncology. 2020;19(6):28–37. doi: 10.21294/1814-4861-2020-19-6-28-37
- Khosravi A, Nemati E, Soleimanian M, et al. Association between prostate specific antigen levels and coronary artery angioplasty. J Renal Inj Prev. 2016;6(2):132–136. doi: 10.15171/jrip.2017.26
- Lee JH, Jee BA, Kim JH, et al. Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2021;13(24):6345. doi: 10.3390/cancers13246345
- Chang Y, Kim JH, Noh JW, et al. Prostate-Specific Antigen Within the Reference Range, Subclinical Coronary Atherosclerosis, and Cardiovascular Mortality. Circ Res. 2019;124(10):1492–1504. doi: 10.1161/CIRCRESAHA.118.313413
- Guo M, Yao J, Li J, et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction. J Cachexia Sarcopenia Muscle. 2023;14(1):391–405. doi: 10.1002/jcsm.13141
- Supriya R, Singh KP, Gao Y, et al. A Multifactorial Approach for Sarcopenia Assessment: A Literature Review. Biology (Basel). 2021;10(12):1354. doi: 10.3390/biology10121354
- Fu J, Li F, Tang Y, et al. The Emerging Role of Irisin in Cardiovascular Diseases. J Am Heart Assoc. 2021;10(20):e022453. doi: 10.1161/JAHA.121.022453
- Zhao M, Zhou X, Yuan C, et al. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Sci Rep. 2020;10(1):16093. doi: 10.1038/s41598-020-73176-z
- Antuña E, Cachán-Vega C, Bermejo-Millo JC, et al. Inflammaging: Implications in Sarcopenia. Int J Mol Sci. 2022;23(23):15039. doi: 10.3390/ijms232315039
- Kirk B, Feehan J, Lombardi G, Duque G. Muscle, Bone, and Fat Crosstalk: the Biological Role of Myokines, Osteokines, and Adipokines. Curr Osteoporos Rep. 2020;18(4):388–400. doi: 10.1007/s11914-020-00599-y
- Colaianni G, Cuscito C, Mongelli T, et al. Irisin enhances osteoblast differentiation in vitro. Int J Endocrinol. 2014;(2014):902186. doi: 10.1155/2014/902186
- Anastasilakis AD, Koulaxis D, Kefala N, et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism. 2017;(73):1–8. doi: 10.1016/j.metabol.2017.05.002
- Kwon JH, Moon KM, Min KW. Exercise-Induced Myokines can Explain the Importance of Physical Activity in the Elderly: An Overview. Healthcare (Basel). 2020;8(4):378. doi: 10.3390/healthcare8040378
- Bekki M, Hashida R, Kawaguchi T, et al. The association between sarcopenia and decorin, an exercise-induced myokine, in patients with liver cirrhosis: a pilot study. JCSM Rapid Communications. 2018;1(2):1–10. doi: 10.1002/j.2617-1619.2018.tb00009
- Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps. Nutrients. 2020;12(8):2401. doi: 10.3390/nu12082401
- Peng LN, Lee WJ, Liu LK, et al. Healthy community-living older men differ from women in associations between myostatin levels and skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2018;9(4):635–642. doi: 10.1002/jcsm.12302
- Skrzypczak D, Skrzypczak-Zielińska M, Ratajczak AE, et al. Myostatin and Follistatin-New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. Biomedicines. 2021;9(10):1301. doi: 10.3390/biomedicines9101301
- Esposito P, Picciotto D, Battaglia Y, et al. Myostatin: Basic biology to clinical application. Adv Clin Chem. 2022;(106):181–234. doi: 10.1016/bs.acc.2021.09.006
- Oliveira PGS, Schwed JF, Chiuso-Minicucci F, et al. Association Between Serum Myostatin Levels, Hospital Mortality, and Muscle Mass and Strength Following ST-Elevation Myocardial Infarction. Heart Lung Circ. 2022;31(3):365–371. doi: 10.1016/j.hlc.2021.08.018
- Ahn SH, Jung HW, Lee E, et al. Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia. Endocrinol Metab (Seoul). 2022;37(3):487–496. doi: 10.3803/EnM.2022.1428
- Kim JA, Roh E, Hong SH, et al. Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS). Bone. 2019;(128):115053. doi: 10.1016/j.bone.2019.115053
- Courtalin M, Bertheaume N, Badr S, et al. Relationships between Circulating Sclerostin, Bone Marrow Adiposity, Other Adipose Deposits and Lean Mass in Post-Menopausal Women. Int J Mol Sci. 2023;24(6):5922. doi: 10.3390/ijms24065922
- Tobias JH. Sclerostin and Cardiovascular Disease. Curr Osteoporos Rep. 2023;21(5):519–526. doi: 10.1007/s11914-023-00810-w
- Frysz M, Gergei I, Scharnagl H, et al. Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors. J Bone Miner Res. 2022;37(2):273–284. doi: 10.1002/jbmr.4467
- Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2022;42(7):e187–e202. doi: 10.1161/ATVBAHA.122.317635
- Bian A, Ma Y, Zhou X, et al. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet Disord. 2020;21(1):214. doi: 10.1186/s12891-020-03236-y
- Tritos NA, Biller BMK. Current concepts of the diagnosis of adult growth hormone deficiency. Rev Endocr Metab Disord. 2021;22(1):109–116. doi: 10.1007/s11154-020-09594-1
- Kopchick JJ, Berryman DE, Puri V, et al. The effects of growth hormone on adipose tissue: old observations, new mechanisms. Nat Rev Endocrinol. 2020;16(3):135–146. doi: 10.1038/s41574-019-0280-9
- Cannarella R, Barbagallo F, Condorelli RA, et al. Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly. J Clin Med. 2019;8(10):1564. doi: 10.3390/jcm8101564
- Obradovic M, Zafirovic S, Soskic S, et al. Effects of IGF-1 on the Cardiovascular System. Curr Pharm Des. 2019;25(35):3715–3725. doi: 10.2174/1381612825666191106091507
- Higashi Y, Gautam S, Delafontaine P, Sukhanov S. IGF-1 and cardiovascular disease. Growth Horm IGF Res. 2019;(45):6–16. doi: 10.1016/j.ghir.2019.01.002
- Rudenka AV, Rudenka EV, Samokhovec VYu, et al. Association of vitamin D receptor gene polymorphism with a bone mineral density level in postmenopausal women. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2019;16(2):192–201. doi: 10.29235/1814-6023-2019-16-2-192-201
- Reid IR. Vitamin D Effect on Bone Mineral Density and Fractures. Endocrinol Metab Clin North Am. 2017;46(4):935–945. doi: 10.1016/j.ecl.2017.07.005
- Vaes AMM, Brouwer-Brolsma EM, Toussaint N, et al. The association between 25-hydroxyvitamin D concentration, physical performance and frailty status in older adults. Eur J Nutr. 2019;58(3):1173–1181. doi: 10.1007/s00394-018-1634-0
- Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014;99(11):4336–4345. doi: 10.1210/jc.2014-1742
- Kim YM, Kim S, Won YJ, Kim SH. Clinical Manifestations and Factors Associated with Osteosarcopenic Obesity Syndrome: A Cross-Sectional Study in Koreans with Obesity. Calcif Tissue Int. 2019;105(1):77–88. doi: 10.1007/s00223-019-00551-y
- Latic N, Erben RG. Vitamin D and Cardiovascular Disease, with Emphasis on Hypertension, Atherosclerosis, and Heart Failure. Int J Mol Sci. 2020;21(18):6483. doi: 10.3390/ijms21186483